KATIE LIN: Open Payments
NPI 1104596535 · ARCADIA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,925 in 78 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $1,236 · 2025 $2,925
Food & beverage: $2,826Education: $99
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $712 |
| Amgen Inc. | 17 | $511 |
| Regeneron Healthcare Solutions, Inc. | 9 | $468 |
| GENZYME CORPORATION | 8 | $324 |
| Novartis Pharmaceuticals Corporation | 5 | $220 |
| LEO Pharma Inc. | 2 | $153 |
| Incyte Corporation | 7 | $142 |
| Galderma Laboratories, L.P. | 2 | $118 |
| Arcutis Biotherapeutics, Inc. | 5 | $110 |
| UCB, Inc. | 1 | $44 |
Products named: DUPIXENT, SKYRIZI, OTEZLA, RINVOQ, OPZELURA, ADBRY, Rhapsido, NEMLUVIO.
Industry payments across CA — which companies pay providers there.
